EGFR Targeted Therapy

Noor, Zorawar S.; Goldman, Jonathan W.

doi:10.1007/978-3-030-17832-1_1

Cited by 2 publications

(1 citation statement)

References 194 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The gene most frequently included as an inclusion criterion across all trials was BRAF (n=46 trials), followed by EGFR (n=42 trials), and KRAS (n=38 trials) (Fig. 3a), reflecting the many therapies in PM trials for these oncogenic drivers 28–30 . Other genes frequently leading to PM trial eligibility included IDH1 (n=24) and IDH2 (n=20), NTRK (n=15), ALK (n=27), and ROS1 (n=12), and homologous recombination repair (HR) genes such as BRCA1 / BRCA2 (n=35) and PALB2 (n=20).…”

Section: Resultsmentioning

confidence: 99%

MatchMiner: An open source platform for cancer precision medicine

Klein

Mazor

Siegel

et al. 2022

Preprint

View full text Add to dashboard Cite

The systematic deployment of next generation sequencing means patient tumors can be genomically profiled and specific genetic alterations can be targeted with precision medicine (PM) drugs. More therapeutic clinical trials are needed to test new PM drugs to advance precision medicine, however, the availability of comprehensive patient sequencing data coupled with complex clinical trial eligibility has made it challenging to match patients to PM trials. To facilitate enrollment onto PM trials, we developed MatchMiner. MatchMiner is an open-source platform to computationally match genomically profiled cancer patients to PM trials. Here, we describe MatchMiner's capabilities, outline its deployment at Dana-Farber Cancer Institute (DFCI), and characterize its impact on PM trial enrollment. MatchMiner's two primary goals are to (1) facilitate PM trial options for all patients, and (2) accelerate trial enrollment onto PM trials. MatchMiner has 3 main modes of use: (1) patient-centric, where a clinician looks up trial options for an individual patient, (2) trial-centric, where a trial team identifies candidate patients for their trial by setting up a filter, and (3) trial search, where a clinician can find trial options for patients that have external genomic reports. From the time MatchMiner was first deployed at DFCI in March 2016 through March 2021, we curated 354 PM trials containing a broad range of genomic and clinical eligibility criteria and MatchMiner facilitated 166 trial consents (MatchMiner consents, MMC) for 159 patients. To quantify MatchMiner's impact on trial consent, we retrospectively measured time from genomic sequencing report date to trial consent date for the 166 MMC compared to trial consents not facilitated by MatchMiner (non-MMC). We found MMC consented to trials 55 days (22%) earlier than non-MMC. MatchMiner has enabled our clinicians to match patients to PM trials and accelerated the trial enrollment decision making process.

show abstract

Section: Resultsmentioning

confidence: 99%

MatchMiner: An open source platform for cancer precision medicine

Klein

Mazor

Siegel

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

MatchMiner: an open-source platform for cancer precision medicine

et al. 2022

View full text Add to dashboard Cite

Widespread, comprehensive sequencing of patient tumors has facilitated the usage of precision medicine (PM) drugs to target specific genomic alterations. Therapeutic clinical trials are necessary to test new PM drugs to advance precision medicine, however, the abundance of patient sequencing data coupled with complex clinical trial eligibility has made it challenging to match patients to PM trials. To facilitate enrollment onto PM trials, we developed MatchMiner, an open-source platform to computationally match genomically profiled cancer patients to PM trials. Here, we describe MatchMiner’s capabilities, outline its deployment at Dana-Farber Cancer Institute (DFCI), and characterize its impact on PM trial enrollment. MatchMiner’s primary goals are to facilitate PM trial options for all patients and accelerate trial enrollment onto PM trials. MatchMiner can help clinicians find trial options for an individual patient or provide trial teams with candidate patients matching their trial’s eligibility criteria. From March 2016 through March 2021, we curated 354 PM trials containing a broad range of genomic and clinical eligibility criteria and MatchMiner facilitated 166 trial consents (MatchMiner consents, MMC) for 159 patients. To quantify MatchMiner’s impact on trial consent, we measured time from genomic sequencing report date to trial consent date for the 166 MMC compared to trial consents not facilitated by MatchMiner (non-MMC). We found MMC consented to trials 55 days (22%) earlier than non-MMC. MatchMiner has enabled our clinicians to match patients to PM trials and accelerated the trial enrollment process.

show abstract

EGFR Targeted Therapy

Cited by 2 publications

References 194 publications

MatchMiner: An open source platform for cancer precision medicine

MatchMiner: An open source platform for cancer precision medicine

MatchMiner: an open-source platform for cancer precision medicine

Contact Info

Product

Resources

About